News
2019
April 1, 2019
Apexigen Presents Clinical Data on CD40 Antibody APX005M
in Metastatic Melanoma at the AACR Annual Meeting 2019
March 31, 2019
Apexigen Announces New Clinical Data on APX005M in Combination
Therapy for Pancreatic Cancer at the AACR Annual Meeting 2019
March 20, 2019
Apexigen Announces Clinical Data Presentations on CD40 Antibody
APX005M at the AACR Annual Meeting 2019
February 19, 2019
Apexigen to present at upcoming Investor Conferences
2018
December 20, 2018
Apexigen announces Clinical Collaboration on a New Phase
2 Trial For APX005M in Sarcoma
December 6, 2018
Neon Therapeutics and Apexigen Announce First Patient Dosed
in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
November 26, 2018
Apexigen To Present At Piper Jaffray’s 30th Annual
Healthcare Conference
August 8, 2018
Apexigen Raises $73 Million In Series B And Series C Financings
May 18, 2018
Apexigen Expands Leadership Team with Appointment of Frances
Rena Bahjat, Ph.D. Vice President, Discovery Research
March 6, 2018
Apexigen and the Pediatric Brain Tumor Consortium Announce
a Clinical Collaboration to Evaluate APX005M in Children with Brain Tumors
Study to evaluate the safety and tolerability of APX005M, a CD40 agonistic antibody,
in pediatric patients with recurrent or refractory brain tumors
2017
October 25, 2017
Apexigen Announces New Collaboration with UCSF
Clinical Trial Collaboration to Evaluate Apexigen’s Immune Activating Antibody
APX005M in Combination with Multimodality Treatment of Resectable Esophageal and Gastro-Esophageal
Junction Cancers
September 20, 2017
The Parker Institute for Cancer Immunotherapy and the Cancer
Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial
Combining Immunotherapy and Chemotherapy
Collaboration with Bristol-Myers Squibb, Apexigen will test CD40 antibody APX005M,
nivolumab and chemotherapy
July 25, 2017
Neon Therapeutics and Apexigen Announce Immuno-Oncology
Clinical Trial Collaboration
March 21, 2017
Phase
1/2 Clinical Trial of Apexigen’s APX005M in Combination with Pembrolizumab (Keytruda®)
Opens for Metastatic Melanoma Patients
March 16, 2017
Apexigen
Receives Clinical Development Milestone Payment under Collaboration Agreement
2016
April 13, 2016
Apexigen to Present Data on Its Novel Immuno-Oncology
Program APX005M at Upcoming Cancer Conferences
2015
November 17, 2015
Apexigen Presents Positive Data for APX005M in Podium Presentation
at Immune Checkpoint Inhibitors (ICI) Europe
November 06, 2015
Apexigen Presents Preclinical Data from Novel Immuno-Oncology
Candidate APX005M at SITC 2015 Meeting
June 22, 2015
3SBio Acquires Global Rights to Anti-TNF mAb Acquisition
expands international product pipeline
June 16, 2015
Apexigen Doses First Patient in Phase 1 Clinical Trial of
Its Immuno-oncology Therapeutic Antibody APX005M
May 06, 2015
Apexigen Selected to Present at Cavendish Global Health
Impact Forum
2013-14
October 15, 2014
Apexigen Strengthens its Management Team with Additions
of Vice President, Clinical Development and Vice President, Finance
Apexigen ranked #4 among US Life Science Start-up Companies by BioSpace (pdf)
October 18, 2013
Apexigen
listed in the Top 20 of the 2013 Biotech Start-up Class of 2013 by Xconomy (pdf)
August 6, 2013
Apexigen Secures $20 Million Series A1 Financing
2010-12
December 5, 2012
Boehringer Ingelheim and Apexigen sign manufacturing agreement
for process development and early stage clinical supply
November 11, 2012
Apexigen Announces Initiation of Clincal Trials by Its Partner,
Simcere Pharmaceutical Group
August 15, 2012
Apexigen Announces the Filing of an IND by its Partner,
3SBio
April 2012
Apexigen
Inc. is Using Antibodies Derived from Rabbits to Develop Therapies in Cancer and Inflammatory
Disease (pdf)
March 11, 2011
Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical
Group, of First IND
December 7, 2010
Apexigen, Inc. Announces Collaboration for Antibody Discovery
November 22, 2010
BioCentury: Emerging
Company Profile - Apexigen: rAbbits hop rodents (pdf)